A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

Last updated:
2026-09-26
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE III, RANDOMISED, DOUBLE-BLIND, STUDY TO EVALUATE THE EFFECT OF BALCINRENONE/DAPAGLIFLOZIN COMPARED WITH DAPAGLIFLOZIN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH CHRONIC KIDNEY DISEASE (STAGE 3B AND 4)

Intervention/treatment:
BALCINRENONE-DAPAGLIFLOZIN (AZD2961) / DAPAGLIFLOZIN
Medical condition:
CHRONIC KIDNEY DISEASE (CKD)
Protocol code:
D8790C00001
Control number:
503904
Status:
Recruiting
Approved:
July 30, 2026
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT07624305
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 99 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
AstraZeneca Clinical Study Information Center
Role
CONTACT
Phone:
+18772409479
Name
AstraZeneca Clinical AstraZeneca Clinical
Role
CONTACT
Phone:
+18772409479
Sponsor
ASTRAZENECA CANADA INC

Locations

Alberta

Research Site
Calgary, Alberta, T2R0X7
WITHDRAWN
Research Site
Edmonton, Alberta, T6G 2P4
NOT_YET_RECRUITING

Manitoba

Research Site
Winnipeg, Manitoba, R2V 3M3
NOT_YET_RECRUITING

Nova Scotia

Research Site
Halifax, Nova Scotia, B3H 2Y9
NOT_YET_RECRUITING

Ontario

Research Site
Brampton, Ontario, L6T 0H9
NOT_YET_RECRUITING
Research Site
Greater Sudbury, Ontario, P3E 5J1
NOT_YET_RECRUITING
Research Site
London, Ontario, N6A 5A5
NOT_YET_RECRUITING
Research Site
Mississauga, Ontario, L5M 2S6
NOT_YET_RECRUITING
Research Site
Oakville, Ontario, L6M 0L8
NOT_YET_RECRUITING
Research Site
Toronto, Ontario, M4G 3E8
NOT_YET_RECRUITING
Research Site
Toronto, Ontario, M5G 2C4
NOT_YET_RECRUITING
Research Site
Waterloo, Ontario, N2T 0C1
RECRUITING

Quebec

Research Site
Montreal, Quebec, H1T 2M4
NOT_YET_RECRUITING
Research Site
Montreal, Quebec, H2X 0A9
NOT_YET_RECRUITING
Research Site
Montreal, Quebec, H3G 1A4
NOT_YET_RECRUITING
Research Site
Montreal, Quebec, H4J 1C5
NOT_YET_RECRUITING
Research Site
Quebec, Quebec, G1R 2J6
NOT_YET_RECRUITING
Did you find what you were looking for?